BH3 profiling to optimize lymphoma treatment: Pre-clinical studies

Myra Langendonk

    Research output: ThesisThesis fully internal (DIV)

    428 Downloads (Pure)

    Abstract

    Unfortunately, lymphoma (Hodgkin's and Non-Hodgkin's lymphoma) is still an incurable disease for many people and new and smart treatment techniques are needed to improve the prognosis of these patients.
    The goal of the research described in this dissertation was to find pre-existing medications used in other cancers, using a technique that allows to test the dependence on anti-apoptotic proteins (proteins important for the survival of cancer cells). This technique is called BH3 profiling.
    By applying this technique, it has been found that tamoxifen, an affordable, anti-hormone drug that has been used in breast cancer for more than 40 years, can kill lymph node cancer cells in laboratory experiments and in animal experimental models. If tamoxifen is combined with a drug that blocks anti-apoptotic proteins, the anticancer effect is enhanced. This has led to a clinical trial in patients with untreatable aggressive lymphoma.
    In addition to these important findings and applications, this thesis describes the efficacy of combinations of different drugs in lymphoma and whether these agents alter the dependence on these anti-apoptotic agents.
    This project was carried out through a KWF grant.
    Original languageEnglish
    QualificationDoctor of Philosophy
    Awarding Institution
    • University of Groningen
    Supervisors/Advisors
    • Huls, Gerwin, Supervisor
    • van den Berg, Anke, Supervisor
    • van Meerten, Tom, Co-supervisor
    • Visser, Lydia, Co-supervisor
    Award date23-Jun-2023
    Place of Publication[Groningen]
    Publisher
    DOIs
    Publication statusPublished - 2023

    Fingerprint

    Dive into the research topics of 'BH3 profiling to optimize lymphoma treatment: Pre-clinical studies'. Together they form a unique fingerprint.

    Cite this